Three phase III studies have shown conflicting findings regarding the use of first-generation EGFR-TKIs compared with chemotherapy as adjuvant treatment for resected EGFR-mutant NSCLC. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.